I'm LongbridgeAI, I can summarize articles.Telomir reported peer-reviewed preclinical data indicating that Telomir-Zn improves survival and reduces hepatic copper in a Wilson’s disease model. Key findings include reduced copper-driven ROS amplification, lower liver injury biomarkers, and improved locomotor performance in zebrafish. The company plans to continue its Wilson’s disease program and advance its Telomir-1 TNBC program toward Phase 1/2 clinical initiation.
Telomir reported peer-reviewed preclinical data showing Telomir‑Zn produced dose-dependent survival improvements and reduced hepatic copper and liver injury markers in a Wilson’s disease model.
Key Highlights:
- Publication in Advances in Redox Research reports Telomir‑Zn reduced copper-driven ROS amplification and intracellular Ca2+ dysregulation.
- Telomir‑Zn reduced hepatic copper accumulation and lowered liver injury biomarkers including ALT, AST, and bilirubin.
- Preclinical results showed improved locomotor performance, reduced tissue degeneration, and dose-dependent survival benefits in a zebrafish model.
- Findings support intracellular copper modulation as a mechanism relevant to oxidative stress and mitochondrial injury pathways.
- Company will continue evaluating the Wilson’s disease program while advancing its Telomir‑1 TNBC program toward Phase 1/2 clinical initiation.
Original SEC Filing: Telomir Pharmaceuticals, Inc. [ TELO ] - 8-K - May. 20, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.